Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)Background: Dara, a human IgGκ monoclonal antibody that targets CD38, is approved in combination with bortezomib, ...
Cybord is an active, well tolerated, cost-effective induction regimen in newly diagnosed multiple myeloma—a single centre experience Blood, 122 (21) (2013), p. 5396 View PDFView articleCrossrefGoogle Scholar 23 M Attal, V Lauwers-Cances, C Hulin, et al., IFM 2009 Study Lenalidomide, bor...